S. J. Goldsmith

Articles by S. J. Goldsmith

Efficacy and Safety of Tositumomab/Iodine-131 Tositumomab in the Expanded Access Study: Interim Report From Two Institutions

ByS. A. Gregory,M. Coleman,A. Ali,T. M. O'Brien,A. Subramanian,L. Kostakoglu,S. J. Goldsmith,N. Valente,J. P. Leonard

March 1st 2001

Relapsed or refractory low-grade non-Hodgkin’s lymphoma (NHL) and transformed low-grade NHL are incurable diseases. Tositumomab/iodine-131 tositumomab (Bexxar) is a novel

Latest Updated Articles

Efficacy and Safety of Tositumomab/Iodine-131 Tositumomab in the Expanded Access Study: Interim Report From Two Institutions
March 1st 2001

S. J. Goldsmith

Articles by S. J. Goldsmith

Efficacy and Safety of Tositumomab/Iodine-131 Tositumomab in the Expanded Access Study: Interim Report From Two Institutions

Latest Updated Articles

Trending on CancerNetwork

Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications

FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer

EU Approves Enfortumab Vedotin/Pembrolizumab in Cisplatin-Ineligible MIBC

GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations

Efficacy of GLP-1 Receptor Agonists in Breast Cancer Populations